← Back
NeuroTrials.ai
Neurology Clinical Trial Database

BP THROMBECTOMY METANALYSIS

Intensive Versus Standard Blood Pressure Control After Endovascular Thrombectomy in Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled Trials

Year of Publication: 2026

Authors: Tallal M. Hashmi, Mushood Ahmed, Hadiah Ashraf, ..., Ameer E. Hassan

Journal: Journal of the American Heart Association

Citation: Hashmi TM, et al. Intensive Versus Standard Blood Pressure Control After Endovascular Thrombectomy in Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2026;15:e045503.

Link: https://doi.org/10.1161/JAHA.125.045503


Clinical Question

Does intensive systolic blood pressure reduction below 130–140 mmHg after successful mechanical thrombectomy improve functional outcomes compared to standard blood pressure management in acute ischemic stroke?

Bottom Line

Intensive post-thrombectomy blood pressure lowering (targeting SBP <130–140 mmHg) does not improve and may worsen outcomes, with significantly reduced good functional recovery, higher all-cause mortality, and markedly increased hypotensive episodes compared to standard management; clinicians should avoid aggressive BP reduction after successful recanalization.

Major Points

  • Meta-analysis of 6 RCTs encompassing 1902 patients demonstrates intensive BP control (SBP targets ranging <120 to <140 mmHg) after thrombectomy does not improve functional outcomes
  • Intensive BP control significantly reduced the likelihood of good functional outcome (mRS 0–2 at 90 days): OR 0.70 (95% CI, 0.54–0.91), P=0.02 — a 30% relative reduction in odds
  • All-cause mortality at 90 days was significantly higher with intensive BP control: OR 1.21 (95% CI, 1.05–1.40), P=0.02
  • Hypotensive episodes were more than twice as common with intensive BP control: OR 2.49 (95% CI, 1.56–3.96), P=0.01
  • No significant difference in excellent functional outcome (mRS 0–1 at 90 days): OR 0.91 (95% CI, 0.67–1.23), P=0.44, I²=23%
  • No significant difference in symptomatic intracranial hemorrhage: OR 1.19 (95% CI, 0.89–1.61), P=0.19
  • Evidence certainty was high for functional outcomes and hypotensive episodes; moderate for all-cause mortality and symptomatic intracranial hemorrhage
  • Current AHA/ASA guidelines recommending SBP ≤180/105 mmHg for ≥24 hours after recanalization are supported by this evidence
  • Postthrombectomy BP management should be approached cautiously — aggressive SBP reduction carries measurable harm without functional benefit

Design

Study Type: Systematic review and meta-analysis of randomized controlled trials

Randomization: 1

Blinding: Varied across included trials

Allocation: Varied across included trials

Enrollment Period: Inception to June 25, 2025 (search date)

Follow-up Duration: 90 days

Centers: 0

Countries: France, China, United States, South Korea, Canada

Sample Size: 1902

Analyzed: 1902

Analysis: Random-effects model; pooled odds ratios with 95% CIs; Hartung-Knapp-Sidik-Jonkman adjustment for CI accuracy; restricted maximum likelihood for between-study variance (τ²); leave-one-out sensitivity analysis; I² for heterogeneity; 95% prediction intervals; GRADE for certainty of evidence

Registration: PROSPERO CRD420251082965


Inclusion Criteria

  • Study design: randomized controlled trials only
  • Population: patients diagnosed with acute ischemic stroke resulting from large vessel occlusion
  • Intervention: intensive blood pressure control post-mechanical thrombectomy
  • Comparator: standard blood pressure control post-mechanical thrombectomy
  • Outcome: reporting at least one relevant outcome of interest

Exclusion Criteria

  • Non-randomized studies (observational studies, post hoc analyses, experimental studies)

Baseline Characteristics

0:

  • Characteristic: Mean Age (years)
  • Control: 73 (range across trials: 67–76.3)
  • Intervention: 75 (range across trials: 68–86)

1:

  • Characteristic: Baseline NIHSS score
  • Control: 9–18 across trials (median ~15)
  • Intervention: 11.3–18.7 across trials (median ~16)

2:

  • Characteristic: Mean SBP before thrombectomy (mmHg)
  • Control: 146–162 across trials
  • Intervention: 150–168 across trials

3:

  • Characteristic: IV thrombolysis (n)
  • Control: BP-TARGET 83; ENCHANTED2/MT 115; BEST-II 19; OPTIMAL-BP 54; DETECT 4; IDENTIFY 85
  • Intervention: BP-TARGET 85; ENCHANTED2/MT 132; BEST-II 17–19; OPTIMAL-BP 44; DETECT 6; IDENTIFY 77

4:

  • Characteristic: mTICI 3 reperfusion (n)
  • Control: BP-TARGET 84; ENCHANTED2/MT 340; BEST-II 16; DETECT 7; IDENTIFY 162 (OPTIMAL-BP NR)
  • Intervention: BP-TARGET 88; ENCHANTED2/MT 342; BEST-II 18; DETECT 8; IDENTIFY 144 (OPTIMAL-BP NR)

5:

  • Characteristic: Onset-to-reperfusion time (min, median)
  • Control: 273–399 across trials
  • Intervention: 285–438 across trials

6:

  • Characteristic: Hypertension (n)
  • Control: BP-TARGET 113; ENCHANTED2/MT 261; BEST-II 32; OPTIMAL-BP 110; DETECT 11; IDENTIFY 134
  • Intervention: BP-TARGET 110; ENCHANTED2/MT 267; BEST-II 32; OPTIMAL-BP 121; DETECT 14; IDENTIFY 134

7:

  • Characteristic: Diabetes (n)
  • Control: BP-TARGET 33; ENCHANTED2/MT 82; BEST-II 13; OPTIMAL-BP 62; DETECT 5; IDENTIFY 45
  • Intervention: BP-TARGET 34; ENCHANTED2/MT 81; BEST-II 12–15; OPTIMAL-BP 65; DETECT 3; IDENTIFY 49

8:

  • Characteristic: Atrial fibrillation (n)
  • Control: ENCHANTED2/MT 98; BEST-II 21; OPTIMAL-BP 69; DETECT 5; IDENTIFY 121 (BP-TARGET NR)
  • Intervention: ENCHANTED2/MT 84; BEST-II 13–19; OPTIMAL-BP 77; DETECT 7; IDENTIFY 112 (BP-TARGET NR)

9:

  • Characteristic: Prior stroke/TIA (n)
  • Control: BP-TARGET 21; ENCHANTED2/MT 139; OPTIMAL-BP 30; DETECT 2; IDENTIFY 37 (BEST-II NA)
  • Intervention: BP-TARGET 25; ENCHANTED2/MT 107; OPTIMAL-BP 36; DETECT 6; IDENTIFY 29 (BEST-II NR)

10:

  • Characteristic: Location of occlusion
  • Control: MCA, ICA (all trials)
  • Intervention: MCA, ICA (all trials)

Arms

FieldIntensive BP ControlControl
N944958
InterventionIntensive blood pressure lowering following successful mechanical thrombectomy. SBP targets varied across trials: BP-TARGET 100–129, ENCHANTED2/MT <120, BEST-II <140 (Group A) / <160 (Group B), OPTIMAL-BP <140, DETECT <140, IDENTIFY <130 mmHg. Randomization occurred within 24 hours of symptom onset in most trials; IDENTIFY exclusively used an early approach with randomization within 6 hours of onset.Standard blood pressure management per AHA/ASA guidelines (SBP ≤180/105 mmHg). SBP targets varied across trials: BP-TARGET 130–185, ENCHANTED2/MT 140–180, BEST-II ≤180, OPTIMAL-BP 140–180, DETECT <180, IDENTIFY <180 mmHg. Randomization within 24 hours of symptom onset (within 6 hours for IDENTIFY).
DurationBP control maintained for at least 24 hours post-recanalization (varied across trials)BP control maintained for at least 24 hours post-recanalization (varied across trials)

Outcomes

OutcomeTypeControlInterventionHR / OR / RRP-value
Excellent functional outcome (mRS 0–1 at 90 days) and good functional outcome (mRS 0–2 at 90 days)PrimaryReference (standard BP control)Intensive BP control0.7P=0.44 for excellent functional outcome (mRS 0–1); P=0.02 for good functional outcome (mRS 0–2)
All-cause death at 90 daysSecondary146/960 (standard BP)166/946 (intensive BP)OR 1.21 (95% CI 1.05-1.40)P=0.02
Symptomatic intracranial hemorrhageSecondary67/967 (standard BP)77/948 (intensive BP)OR 1.19 (95% CI 0.89-1.61)P=0.19
Hypotensive episodesSecondary96/510 (standard BP)162/494 (intensive BP)OR 2.49 (95% CI 1.56-3.96)P=0.01
Hypotensive episodesSafetyOR 2.49 (95% CI, 1.56–3.96)
Symptomatic intracranial hemorrhageSafetyOR 1.19 (95% CI, 0.89–1.61)
All-cause mortality at 90 daysSafetyOR 1.21 (95% CI, 1.05–1.40)

Subgroup Analysis

Leave-one-out sensitivity analysis conducted, sequentially excluding each of the 6 RCTs to evaluate effect on overall results; exclusion of BP-TARGET trial noted to affect excellent functional outcome sensitivity analysis


Criticisms

  • Only 6 RCTs included — insufficient number for funnel plot analysis or formal publication bias assessment
  • Heterogeneity in BP targets across trials (SBP <120 to <140 mmHg for intensive; ≤180 to 140–180 mmHg for standard) may limit interpretability of pooled estimates
  • Blinding varied across included trials, introducing potential performance and detection bias
  • Baseline characteristics differed across trials conducted in different countries and healthcare systems
  • Timing of BP intervention (within 6 hours vs within 24 hours of symptom onset) varied across trials — IDENTIFY was the only early intensive trial
  • 4 of 6 trials judged to have some concerns for risk of bias; ENCHANTED2/MT and DETECT rated as low overall risk

Funding

None.

Based on: BP THROMBECTOMY METANALYSIS (Journal of the American Heart Association, 2026)

Authors: Tallal M. Hashmi, Mushood Ahmed, Hadiah Ashraf, ..., Ameer E. Hassan

Citation: Hashmi TM, et al. Intensive Versus Standard Blood Pressure Control After Endovascular Thrombectomy in Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2026;15:e045503.

Content summarized and formatted by NeuroTrials.ai.